New York State Common Retirement Fund Sells 37,691 Shares of Moderna, Inc. (NASDAQ:MRNA)

New York State Common Retirement Fund lessened its holdings in Moderna, Inc. (NASDAQ:MRNA) by 7.6% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 455,407 shares of the company’s stock after selling 37,691 shares during the period. New York State Common Retirement Fund owned approximately 0.12% of Moderna worth $45,290,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company raised its holdings in shares of Moderna by 77.3% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 3,876,147 shares of the company’s stock worth $400,367,000 after buying an additional 1,690,341 shares in the last quarter. Invesco Ltd. raised its stake in Moderna by 19.8% during the third quarter. Invesco Ltd. now owns 3,126,028 shares of the company’s stock worth $322,887,000 after acquiring an additional 517,683 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of Moderna by 9.3% during the third quarter. Wellington Management Group LLP now owns 5,611,119 shares of the company’s stock valued at $579,572,000 after acquiring an additional 476,201 shares during the period. Bamco Inc. NY lifted its holdings in shares of Moderna by 4,863.6% during the third quarter. Bamco Inc. NY now owns 426,869 shares of the company’s stock valued at $44,091,000 after acquiring an additional 418,269 shares during the period. Finally, abrdn plc boosted its stake in shares of Moderna by 477.5% in the 4th quarter. abrdn plc now owns 483,574 shares of the company’s stock valued at $48,091,000 after purchasing an additional 399,843 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Moderna Stock Up 0.9 %

Shares of NASDAQ MRNA opened at $108.85 on Thursday. Moderna, Inc. has a fifty-two week low of $62.55 and a fifty-two week high of $142.79. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42. The company’s 50 day simple moving average is $101.85 and its 200 day simple moving average is $93.64.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, February 22nd. The company reported $0.55 EPS for the quarter, beating the consensus estimate of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company had revenue of $2.80 billion during the quarter, compared to analysts’ expectations of $2.53 billion. During the same quarter in the previous year, the company posted $3.61 EPS. The business’s revenue for the quarter was down 44.9% compared to the same quarter last year. On average, research analysts anticipate that Moderna, Inc. will post -7.51 earnings per share for the current fiscal year.

Insider Transactions at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $109.06, for a total value of $1,635,900.00. Following the sale, the director now directly owns 2,101,931 shares in the company, valued at approximately $229,236,594.86. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Noubar Afeyan sold 15,000 shares of the firm’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $109.06, for a total transaction of $1,635,900.00. Following the sale, the director now owns 2,101,931 shares of the company’s stock, valued at approximately $229,236,594.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO James M. Mock sold 647 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total value of $61,186.79. Following the completion of the sale, the chief financial officer now owns 4,300 shares of the company’s stock, valued at $406,651. The disclosure for this sale can be found here. In the last ninety days, insiders sold 109,954 shares of company stock worth $11,533,976. 15.70% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on the stock. HSBC reissued a “reduce” rating and set a $86.00 price target (up from $75.00) on shares of Moderna in a report on Monday, February 26th. Oppenheimer raised Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 target price on the stock in a report on Tuesday, January 2nd. Royal Bank of Canada restated an “outperform” rating and set a $125.00 price target on shares of Moderna in a research report on Thursday, March 28th. Canaccord Genuity Group lifted their price objective on Moderna from $82.00 to $91.00 and gave the company a “hold” rating in a research report on Friday, February 23rd. Finally, William Blair reissued a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $126.49.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.